Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer.
Eisai Limited, Hatfield, UK.
Department of Nuclear Medicine and Institute of Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland.
Medical Oncology Department, Hospital Vall d'Hebrón, Barcelona, Spain.
Eisai Inc., Woodcliff Lake, NJ, USA.
- Published Article
British Journal of Clinical Pharmacology
Wiley (Blackwell Publishing)
- Publication Date
The significant effects of several covariates on lenvatinib PK variability were small in magnitude, and therefore were not considered clinically relevant, or to warrant any dose adjustment.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 07/07/2017 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/26879594